ION582 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
201アンジェルマン症候群1

201. アンジェルマン症候群


臨床試験数 : 24 薬物数 : 35 - (DrugBank : 9) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05127226
(ClinicalTrials.gov)
December 22, 20219/11/2021HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeHALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman SyndromeAngelman SyndromeDrug: ION582Ionis Pharmaceuticals, Inc.NULLRecruiting2 Years50 YearsAll44Phase 1/Phase 2United States